CAM
CRSP icon

Congress Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Congress Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.97M Buy
109,453
+1,082
+1% +$57K 0.04% 248
2026
Q1 		$5.16M Buy
108,371
+45,035
+71% +$2.38M 0.04% 245
2025
Q4 		$3.32M Sell
63,336
-4,774
-7% -$286K 0.02% 254
2025
Q3 		$4.41M Sell
68,110
-294
-0.4% -$16.9K 0.03% 238
2025
Q2 		$3.33M Buy
68,404
+102
+0.1% +$3.95K 0.02% 253
2025
Q1 		$2.32M Sell
68,302
-437
-0.6% -$18.5K 0.02% 265
2024
Q4 		$2.71M Buy
68,739
+2,971
+5% +$140K 0.02% 267
2024
Q3 		$3.09M Buy
65,768
+1,788
+3% +$90.7K 0.02% 255
2024
Q2 		$3.46M Sell
63,980
-625
-1% -$36.2K 0.02% 249
2024
Q1 		$4.4M Buy
64,605
+24,303
+60% +$1.74M 0.03% 231
2023
Q4 		$2.52M Buy
40,302
+42
+0.1% +$2.32K 0.02% 283
2023
Q3 		$1.83M Buy
+40,260
New +$2.08M 0.02% 282
2021
Q1 		– Sell
-16,695
Closed -$2.56M – 358
2020
Q4 		$2.56M Buy
16,695
+170
+1% +$20.1K 0.02% 228
2020
Q3 		$1.38M Hold
16,525
– – 0.02% 243
2020
Q2 		$1.21M Buy
16,525
+375
+2% +$21.9K 0.01% 250
2020
Q1 		$685K Hold
16,150
– – 0.01% 272
2019
Q4 		$984K Sell
16,150
-26,940
-63% -$1.47M 0.01% 281
2019
Q3 		$1.77M Hold
43,090
– – 0.02% 262
2019
Q2 		$2.03M Buy
43,090
+23,530
+120% +$940K 0.03% 269
2019
Q1 		$699K Buy
+19,560
New +$676K 0.01% 309

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Congress Asset Management's CRSP Position: Q2 2026 in Review

Congress Asset Management increased its CRISPR Therapeutics (CRSP) stake by 1% in Q2 2026, buying an estimated $57K and bringing the position to 109,453 shares worth $5.97M. The position accounts for 0.04% of the portfolio, ranked #248.

Congress Asset Management first reported a position in CRSP in Q1 2019 and has held it in 20 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Congress Asset Management held 109,453 shares of CRISPR Therapeutics worth $5.97M as of Q2 2026.
  • Congress Asset Management bought 1,082 CRISPR Therapeutics shares in Q2 2026, an estimated $57K.
  • CRISPR Therapeutics made up 0.04% of Congress Asset Management's portfolio in Q2 2026, its #248 holding.
  • Congress Asset Management first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 20 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.